ATO has no therapeutic potential on different subtypes of APL (PLZF-RARα–driven APL), due to the fact that the therapeutic efficiency of this drug is dictated by its binding to the PML moiety of PML-RARα [18,19]. Here, RARA is linked to acute promyelocytic leukemia.